In my mind this is the most significant announcement made to...

In my mind this is the most significant announcement made to date by IHL for a number of reasons.

Hydroxychloroquine under the brand name plaquenil is widely prescribed for the treatment of rheumatoid arthritis, in fact I have a relative who is prescribed it and has been for some time.

There is no questioning its effectiveness as a treatment however in some instances the toxicity can cause cardio problems and retinal problems. We KNOW that HCQ works in humans with these potential side effects which quite often deter some doctors from prescribing it for this indication.

The key to this announcement is that IHL 675A has reduced the HCQ content by up to 90% and exceeded the anti inflammatory response of HCQ alone! This in my view is extraordinary as it almost certainly eliminates the toxicity issues surrounding HCQ.

We know that HCQ works as a treatment in humans for rheumatoid arthritis, we also know that CBD is readily prescribed and taken as a treatment for rheumatoid arthritis - and don't just take my word for it, there are countless studies discussing the effectiveness of both treatments and the results today show that the IHL 675A combination blows both individual treatments out of the water. IMO I think it is extremely unlikely that we won't see a similar response in humans because again we know the individual constituents work.

There has been a continual demonstration in vivo of superior performance and synergistic effect of CBD and HCQ in combination over and over again and the thematic I believe is seriously compelling.

Ted.